Celldex Therapeutics (CLDX) Accounts Payables (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Accounts Payables of $10.4 million for Q1 2026, up 203.78% year-over-year from $3.4 million in Q1 2025, and up 777.88% quarter-over-quarter from $1.2 million in Q4 2025.
Celldex Therapeutics (CLDX) Accounts Payables (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $10.4 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 203.78% year-over-year to $10.4 million; the TTM figure through Mar 2026 stood at $10.4 million (up 203.78% YoY), while the FY2025 annual figure was $1.2 million, down 63.86% from the prior year.
- Accounts Payables for Q1 2026 stood at $10.4 million, up from $1.2 million in the prior quarter.
- The five-year high for Accounts Payables was $10.4 million in Q1 2026, with the low at $881000.0 in Q2 2023.
- The 5-year median for Accounts Payables is $3.3 million (2024), against an average of $3.0 million.
- Peak annual rise in Accounts Payables reached 331.56% in 2024, while the deepest fall reached 68.93% in 2024.
- Celldex Therapeutics' Accounts Payables stood at $3.3 million in 2022, then gained by 4.61% to $3.5 million in 2023, then fell by 6.55% to $3.3 million in 2024, then tumbled by 63.86% to $1.2 million in 2025, then jumped by 777.88% to $10.4 million in 2026.
- Business Quant data shows CLDX's Accounts Payables at $10.4 million in Q1 2026, $1.2 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 14.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.68 Mn |
| Mar 31, 2026 | 10.36 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Jun 30, 2025 | 2.07 Mn |
| Mar 31, 2025 | 3.41 Mn |
| Dec 31, 2024 | 3.27 Mn |
| Sep 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 3.80 Mn |
| Mar 31, 2024 | 3.23 Mn |
| Dec 31, 2023 | 3.49 Mn |
| Sep 30, 2023 | 3.59 Mn |
| Jun 30, 2023 | 881,000.00 |
| Mar 31, 2023 | 3.37 Mn |
| Dec 31, 2022 | 3.34 Mn |
| Sep 30, 2022 | 2.27 Mn |
| Jun 30, 2022 | 902,000.00 |
| Mar 31, 2022 | 1.02 Mn |
| Dec 31, 2021 | 1.23 Mn |
| Sep 30, 2021 | 836,000.00 |